mRNA plasmid-based DNA vaccines, and advanced modalities using viral vectors, are at the forefront of the fight against cancer, cardiovascular, immunological, and infectious diseases. To reach their full potential and benefit as many patients as possible, however, workflows used for their manufacture must achieve greater efficiency. A critical step in the process is production of plasmid DNA (pDNA), which traditionally, delivers low yields and requires complex purification schemes. This new process development book provides you with guidance for your plasmid…

Biopharmaceutical manufacturers across the globe are trying to rapidly expand their production capacity to meet the growing demand for new therapies. A key challenge they face is to scale that expansion cost-effectively while protecting the quality and integrity of their production processes. One way they are achieving this growth is through expanded use of single-use systems (SUS). This informative new Avantor® Technical Article details several ways SUS technology can help improve throughput and productivity in key downstream processes that routinely…